Radioimmunotherapy of lymphoma using anti-CD20 antibodies

  • US 6,565,827 B1
  • Filed: 08/07/2001
  • Issued: 05/20/2003
  • Est. Priority Date: 09/16/1993
  • Status: Expired due to Fees
First Claim
Patent Images

1. A composition, comprising:

  • (1) a radioactively labeled monoclonal antibody or radioactively labeled monoclonal antibody fragment in an amount providing 13 to 150 mCi of radioactivity and providing irradiation in a dose range of 10 to 200 cGy to the whole body of a human patient, said amount being effective for achieving remission of B-cell lymphoma in the patient, wherein said antibody or said antibody fragment binds to CD20 antigen present on the surface of cells of B-cell lymphoma, wherein the amount of radioactivity that labels the antibody or antibody fragment is less than the amount which causes myelosuppression severe enough to require the reintroduction of hematopoietic stem cells into said patient in order for the patient to recover hematopoietic function, and wherein said radioactively is provided by 90Y, and (2) a pharmaceutically acceptable carrier.

View all claims

    Thank you for your feedback